From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cance ...
Location: United Kingdom, England, Newcastle upon Tyne
Total raised: $3.2M
Investors 2
| Date | Name | Website |
| - | Esperante | esperante.... |
| - | Northstar ... | northstarv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2022 | - | $3.2M | Future Pla... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 12.09.2022 | 15 U.K.-Based Venture Capital Investors Supporting Underrepr... | These 15 U.K.-based angels and venture capital investors are worth following on the topic of ... [+]... | forbes.com... |
| 22.04.2022 | Exclusive: AngelList raises $44 million from 10% of its cust... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 21.04.2022 | Newcastle’s AMLo gets £2.45 million-shot to facilitate early... | UK-based medical device company that specialises in the early detection of skin cancers, AMLo Biosci... | tech.eu/20... |
| - | Newcastle’s AMLo gets £2.45 million-shot to facilitate early... | UK-based medical device company that specialises in the early detection of skin cancers, AMLo Biosci... | tech.eu/20... |